Encoraf 75 mg (Encorafenib INN)
Targeted BRAF Inhibitor for Advanced Cancer Therapy
💊 Pharmacology:
Encorafenib is a potent and selective BRAF inhibitor targeting the BRAF V600 mutation, a driver of abnormal cell proliferation in certain cancers. By blocking this pathway, Encoraf®:
-
Inhibits tumor cell signaling and growth
-
Reduces cancer cell survival
-
Enhances effectiveness when combined with MEK or EGFR inhibitors
-
Helps delay disease progression
This targeted action provides precision therapy with improved clinical outcomes in mutation-positive tumors.
📌 Indications:
Encoraf® 75 mg is indicated for:
Treatment should be guided by confirmed genetic testing.
💉 Dosage & Administration:
-
Dose and schedule must be determined by an oncologist
-
Administered orally once daily or as prescribed
-
Can be taken with or without food
-
Swallow capsules whole with water
-
Dose adjustments may be required for toxicity management
Patients should follow prescribed combination therapy protocols strictly.
⚠️ Precautions & Warnings:
Careful monitoring is required during therapy:
-
Risk of secondary skin malignancies — regular skin exams recommended
-
Cardiac monitoring when used in combination regimens
-
Liver function monitoring advised
-
Watch for signs of bleeding or vision disturbances
-
Sun sensitivity — protective measures recommended
Promptly report unusual symptoms to healthcare providers.
❌ Contraindications:
🤰 Pregnancy & Lactation:
-
May cause fetal harm — avoid use during pregnancy
-
Effective contraception required during treatment
-
Breastfeeding should be discontinued during therapy and for a recommended time after last dose
⚕️ Side Effects:
Common side effects may include:
-
Fatigue
-
Nausea
-
Abdominal pain
-
Joint pain
-
Rash
-
Diarrhea
-
Hair thinning
Serious but less common effects:
-
Skin cancers
-
Cardiac rhythm changes
-
Liver abnormalities
-
Severe bleeding
🧊 Storage Conditions:
-
Store below 30°C
-
Protect from moisture and direct sunlight
-
Keep in original packaging
-
Keep out of reach of children